Triose Phosphate Isomerase: Difference between revisions
Gregg Snider (talk | contribs) No edit summary |
Gregg Snider (talk | contribs) No edit summary |
||
| Line 55: | Line 55: | ||
== Disease == | == Disease == | ||
{{STRUCTURE_2ypi| PDB=2ypi | SCENE=Triose_Phosphate_Isomerase/Glu104/1}} | {{STRUCTURE_2ypi| PDB=2ypi | SCENE=Triose_Phosphate_Isomerase/Glu104/1}} | ||
'''Triose Phosphate Isomerase Deficiency''': Initially described in 1965, TPI deficiency is an autosomal recessive inherited disorder with characteristics ranging from chronic haemolytic anaemia, increased susceptibility to infections, severe neurological dysfunction, and often times death in early childhood.<ref>PMID:10916682</ref> TPI has been most closely linked to a point mutation at the <scene name='Triose_Phosphate_Isomerase/Glu_104/3'>Glu104</scene> residue which results in the <scene name='Triose_Phosphate_Isomerase/Glu104asp2/1'>Glu104Asp</scene> mutation. A common marker for TPI deficiency is the increased accumulation of dihydroxyacetone phosphate in erythrocyte extracts as a result in the inability of the mutant enzyme to catalyze the isomerization to D-glyceraldehyde-3-phosphate. Recent evidence has indicated that the point mutation does not prove detrimental to the rate of catalysis of the enzyme, but rather effects the ability of the enzyme to dimerize.<ref>PMID:17183658</ref> | '''Triose Phosphate Isomerase Deficiency''': Initially described in 1965, TPI deficiency is an autosomal recessive inherited disorder with characteristics ranging from chronic haemolytic anaemia, increased susceptibility to infections, severe neurological dysfunction, and often times death in early childhood.<ref>PMID:10916682</ref> TPI has been most closely linked to a point mutation at the <scene name='Triose_Phosphate_Isomerase/Glu_104/3'>Glu104</scene> residue which results in the <scene name='Triose_Phosphate_Isomerase/Glu104asp2/1'>Glu104Asp</scene> mutation. A common marker for TPI deficiency is the increased accumulation of dihydroxyacetone phosphate in erythrocyte extracts as a result in the inability of the mutant enzyme to catalyze the isomerization to D-glyceraldehyde-3-phosphate. Recent evidence has indicated that the point mutation does not prove detrimental to the rate of catalysis of the enzyme, but rather effects the ability of the enzyme to dimerize.<ref>PMID:17183658</ref> | ||